EIF3A and cancer: The altered expression of eIF3 subunits has been found in a wide range of tumour entities, including breast cancer [19–21], gastric cancer [22], NSCLC [23], and liver cancer [24], supporting their high potential use as prognostic biomarkers and therapeutic cancer targets.